DiaMedica Power Schritte bij Präeklampsie-Behandlung met Genehmigung für Klinische Studie van Investing.com

MINNEAPOLIS – DiaMedica Therapeutics Inc. (NASDAQ: DMAC), a clinical-stage biopharmaceutical, has halted South African Healthcare (SAHPRA) treatment to begin a Phase 2 trial of Präeklampsie’s proprietary recombinant serin protease DM199. The von Forschern started the study on 26.06.2024 by the Ethikkomitee für Gesundheitsforschung der Universität Stellenbosch genehmigt.

That study is being conducted at the Tygerberg Hospital in Kapstadt, South Africa, under the supervision of Prof. Catherine Cluver, MD, PhD, als Hauptprüferin durchgeführt. DiaMedica will begin dosing in the fourth quarter of 2024 and will begin treatment for the first part of the study in the first half of 2025.

Präeklampsie is een schwerwiegende Schwangerschaftskomplikation, die bis 8% van de Schwangerschaften weltweit berifft. If the symptoms occur with bluthochdruck and organ damage, the high kidneys and leber are intriguing. There are no other treatment lamp therapies available in the US and Europe.

The previous Phase 2 Study included 90 women with preeclampsia and 30 probands with fetal pregnancies. The first study on the examination of the health of DM199, the recovery of maternal blood pressure and the examination of the uterine infection to the cervix to the uterus during pregnancy.

DM199, which can develop as rinvecalinase alfa, is a recombinant form of human gewebekallikrein-1 (rhKLK1) and would not cause Präeklampsia, but also the harmful Schlaganfall. It is often thought that the enzyme is a Schlüsselrolle in the regulated physiological processes, a production of nitrogen monoxide and prostacyclin, which ensures the interdependence of the whole.

DiaMedica Therapeutics is engaged in the treatment of schweren ischämischen Erkrankungen, one of the most influential schlaganfalls and preeklampsia, with its main candidates DM199. These analyzes are based on a press conference and reflect the findings of the internal studies for the clinical trial more broadly.

In other cases, DiaMedica Therapeutics has made a strong contribution to the ReMEDy2 Study trial, which will undergo full recruitment until the first quarter of 2025. If the plant is decommissioned, DM199 as a possible treatment for the treatment of the lamp, will starting patient recruitment in four years a quarter of those years.

HC Wainwright has performed the treatment of DiaMedica Therapeutics with a Kaufempfehlung treatment and a rate of 7 US dollar festivities. The assessment is based on the potential of DM199, which is the basis for the risk assessment treatment.

Finanziell befindet sich DiaMedica in a robust low with 54.1 million US dollars in Barmitteln and Investitionen on 30.06.2024. Trotz eines forecasts moderate Anstiegs der Forschungs- und Entwicklungkosten being general and administrative Ausgaben in Vergleich zum Vorjahr sunk. Increasingly higher values ​​are brought to the market by printing paper. These young people have undone the involvement of DiaMedica Therapeutics, in clinical trials can take a solid financial position.

InvestingPro Acknowledgment

DiaMedica Therapeutics Inc. (NASDAQ: DMAC) is authorized to develop a clinical lung program, which will enable the development of a phase 2 trial in South Africa. This fortschritt is reflected in the market performance of the Unternehmens broader, wobei InvestingPro-Daten a brand turnover trend of 107.59% in one year.

The cause of the independence in treatment is an uncovered medical business to protect the financial position. Laut InvestingPro-Tipps verügt DiaMedica more than Barmittel as debt in the fish program Bilanz, was the notinnen financial flexibility of the research into clinical studies and research reinforcements that are possible.

Due to the positive dynamics of the Aktienkurses, which DMAC trades at 52-Wochen-Hoch, the beach where the Unternehmen are not profitable. An InvestingPro Tipp knows that the analysts do not know what can make their companies profitable in those years. Since there is no new life in biopharmaceutical medicine in the clinical phase, problems and problems are often solved that give priority to the rental.

The market has a potential to make a number of trips, as the Kurs-Buchwert-Verhältnis von 3.72 des Unternehmens says. Investors are probably planning to make the DiaMedica action strongly profitable, the involvement of the Unternehmens for the letzten-zwolf Monate bis zum zweiten Quartal 2024 at -22.38 Million US-Dollar lies, the laufenden Investitionen in Seine Pipeline was unperturbed .

Before then, if you analyze some of the interest, you can give InvestingPro 11 other tips for DMAC, an overview of the financial prosperity and market position of our external companies.

This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.